• We have a fully funded Phase 3 clinical program in a global partnership for Pracinostat worth up to $464 million.

    Read Our 2017 Annual Review

  • Emerging data positions our second drug candidate, a highly differentiated PI3K delta inhibitor, toward a pivotal study in the coming year.

    Read Our 2017 Annual Review

  • Our newest asset, a selective CDK inhibitor with potent inhibition of CDK9, addresses resistance to potential blockbuster drug Venclexta.

    Read Our 2017 Annual Review

  • We are led by a world-class management team with proven experience in oncology drug development, from discovery to approval.

    Read Our 2017 Annual Review

LATEST NEWS

MEI Pharma Reports First Quarter Fiscal Year 2018 Results
Press Release


Presentation at Stifel 2017 Healthcare Conference

Press Release


Presentation at Cantor Global Healthcare Conference
Webcast


Fireside Chat at Wells Fargo Healthcare Conference
Webcast


Exclusive License Agreement with Presage Biosciences for Voruciclib
Press Release


MEI Pharma Reports Fiscal Year 2017 Results
Press Release | Webcast


First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in AML
Press Release


First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in MDS
Press Release